Thiotepa-induced myelosuppression

Review of 670 bladder instillations

M. S. Soloway, K. S. Ford

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Intravesical chemotherapy is an integral part of the therapeutic strategy for patients with superficial bladder cancer. Despite the introduction of new agents thiotepa is used most owing to its low cost and moderate effectiveness. Myelosuppression is a side effect caused by absorption of the drug through the bladder mucosa. A review of 670 instillations of thiotepa in 72 patients at our medical center revealed a decrease in the white or platelet count below normal in 18 per cent of the patients (3.9 per cent of the instillations). In no case did this decrease lead to any problem other than a delay in therapy.

Original languageEnglish
Pages (from-to)889-891
Number of pages3
JournalJournal of Urology
Volume130
Issue number5
StatePublished - Dec 1 1983
Externally publishedYes

Fingerprint

Thiotepa
Intravesical Administration
Platelet Count
Urinary Bladder Neoplasms
Cost-Benefit Analysis
Mucous Membrane
Urinary Bladder
Drug Therapy
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Urology

Cite this

Soloway, M. S., & Ford, K. S. (1983). Thiotepa-induced myelosuppression: Review of 670 bladder instillations. Journal of Urology, 130(5), 889-891.

Thiotepa-induced myelosuppression : Review of 670 bladder instillations. / Soloway, M. S.; Ford, K. S.

In: Journal of Urology, Vol. 130, No. 5, 01.12.1983, p. 889-891.

Research output: Contribution to journalArticle

Soloway, MS & Ford, KS 1983, 'Thiotepa-induced myelosuppression: Review of 670 bladder instillations', Journal of Urology, vol. 130, no. 5, pp. 889-891.
Soloway, M. S. ; Ford, K. S. / Thiotepa-induced myelosuppression : Review of 670 bladder instillations. In: Journal of Urology. 1983 ; Vol. 130, No. 5. pp. 889-891.
@article{3fb574a50a754111b511ef33a4456053,
title = "Thiotepa-induced myelosuppression: Review of 670 bladder instillations",
abstract = "Intravesical chemotherapy is an integral part of the therapeutic strategy for patients with superficial bladder cancer. Despite the introduction of new agents thiotepa is used most owing to its low cost and moderate effectiveness. Myelosuppression is a side effect caused by absorption of the drug through the bladder mucosa. A review of 670 instillations of thiotepa in 72 patients at our medical center revealed a decrease in the white or platelet count below normal in 18 per cent of the patients (3.9 per cent of the instillations). In no case did this decrease lead to any problem other than a delay in therapy.",
author = "Soloway, {M. S.} and Ford, {K. S.}",
year = "1983",
month = "12",
day = "1",
language = "English",
volume = "130",
pages = "889--891",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Thiotepa-induced myelosuppression

T2 - Review of 670 bladder instillations

AU - Soloway, M. S.

AU - Ford, K. S.

PY - 1983/12/1

Y1 - 1983/12/1

N2 - Intravesical chemotherapy is an integral part of the therapeutic strategy for patients with superficial bladder cancer. Despite the introduction of new agents thiotepa is used most owing to its low cost and moderate effectiveness. Myelosuppression is a side effect caused by absorption of the drug through the bladder mucosa. A review of 670 instillations of thiotepa in 72 patients at our medical center revealed a decrease in the white or platelet count below normal in 18 per cent of the patients (3.9 per cent of the instillations). In no case did this decrease lead to any problem other than a delay in therapy.

AB - Intravesical chemotherapy is an integral part of the therapeutic strategy for patients with superficial bladder cancer. Despite the introduction of new agents thiotepa is used most owing to its low cost and moderate effectiveness. Myelosuppression is a side effect caused by absorption of the drug through the bladder mucosa. A review of 670 instillations of thiotepa in 72 patients at our medical center revealed a decrease in the white or platelet count below normal in 18 per cent of the patients (3.9 per cent of the instillations). In no case did this decrease lead to any problem other than a delay in therapy.

UR - http://www.scopus.com/inward/record.url?scp=0021034128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021034128&partnerID=8YFLogxK

M3 - Article

VL - 130

SP - 889

EP - 891

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -